Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection

Timotius Ivan Hariyanto a, Andree Kurniawan b, *

a Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, 15811, Indonesia
b Department of Internal Medicine, Faculty of Medicine, Pelita Harapan University, Boulevard Jendral Sudirman Street, Karawaci, Tangerang, 15811, Indonesia

ARTICLE INFO

Keywords:
Coronavirus disease 2019
COVID-19
Metformin
Diabetes
Treatment

ABSTRACT

Background and aims: The coronavirus disease 2019 (COVID-19) pandemic has caused a significant impact on all aspects of life. One of the comorbidities associated with severe outcome and mortality of COVID-19 is diabetes. Metformin is one of the drugs which is most commonly used for the treatment of diabetes patients. This study aims to analyze the potential benefit of metformin use in reducing the mortality rate from COVID-19 infection.

Methods: We systematically searched the Google Scholar database using specific keywords related to our aims until August 3rd, 2020. All articles published on COVID-19 and metformin were retrieved. Statistical analysis was done using Review Manager 5.4 software.

Results: A total of 5 studies with a total of 6937 patients were included in our analysis. Our meta-analysis showed that metformin use is associated with reduction in mortality rate from COVID-19 infections [RR 0.54 (95% CI 0.32–0.90), p = 0.02, I² = 54%, random-effect modelling].

Conclusion: Metformin has shown benefits in reducing the mortality rate from COVID-19 infections. Patients with diabetes should be advised to continue taking metformin drugs despite COVID-19 infection status.

1. Introduction

The global pandemic disease declared by the World Health Organization (WHO), coronavirus disease 2019 (COVID-19), has been caused a significant burden in health and economic aspects around the world. Until now, the number of positive and death cases is still increasing. Therefore, identification of the factors that involve in the development of the severe disease is very important to enable stratification of risk, optimize the reallocation of hospital resources, and guide public health recommendations and interventions. Several comorbid conditions such as hypertension, diabetes, cardiovascular disease, dyslipidemia, and thyroid disease have been identified to be associated with the development of severe outcomes from COVID-19 (Huang et al., 2020; Hariyanto and Kurniawan, 2020a, 2020b). One of the drugs most commonly taken by diabetes patients is metformin. Metformin has demonstrated beneficial effects in lowering blood glucose in patients with diabetes (Bramante et al., 2020). However, the association between metformin use and COVID-19 has not yet been established. This study aims to analyze the potential association between metformin use and the mortality rate from COVID-19 infection.

2. Materials and methods

We conducted a systematic search of the literature on Google scholar using the keywords “metformin” OR “biguanides” AND “coronavirus disease 2019” OR “COVID-19”, until the present time (August 3rd, 2020) with language restricted to English only. The title, abstract, and full text of all articles identified that matched the search criteria were assessed, and those reporting the rate of metformin use in COVID-19 patients with a clinically validated definition of “mortality” were included in this meta-analysis. The references of all identified studies were also analyzed (forward and backward citation tracking) to identify other potentially eligible articles.

A meta-analysis was performed using Review Manager 5.4 (Cochrane Collaboration) software. Dichotomous variables were calculated using the Mantel-Haenszel formula with random-effects models. We used the I² statistic to assess the heterogeneity, value of <25%, 26–50%, and >50% considered as low, moderate, and high degrees of heterogeneity, respectively. The effect estimate was reported as risk ratio (RR) along with its 95% confidence intervals (CIs) for dichotomous variables, respectively. P-value was two-tailed, and the statistical
0.32 – from COVID-19 infection, with high heterogeneity [RR 0.54 (95% CI significant association of metformin use with reduction of mortality rate pooled RRs for the association between metformin use and mortality rate from COVID-19 is shown in Fig. 1. Our pooled analysis showed a included studies are summarized in Table 1, whilst the individual and searches and other ways. After screening titles, abstracts, and full texts, 5 et al., 2020; Wang et al., 2020) with a total of 6937 COVID-19 patients 3. Results A total of 8110 records were obtained through systematic electronic searches and other ways. After screening titles, abstracts, and full texts, 5 studies (Bramante et al., 2020; Chen et al., 2020; Crouse et al., 2020; Luo et al., 2020; Wang et al., 2020) with a total of 6937 COVID-19 patients were included in the meta-analysis. The essential characteristics of the included studies are summarized in Table 1, whilst the individual and pooled RR for the association between metformin use and mortality rate from COVID-19 is shown in Fig. 1. Our pooled analysis showed a significant association of metformin use with reduction of mortality rate from COVID-19 infection, with high heterogeneity [RR 0.54 (95% CI 0.32–0.90), p = 0.02, I² = 54%, random-effect modelling].

4. Discussion Based on our meta-analysis of available data, metformin use seems to be associated with a reduced risk of mortality from COVID-19 infection. Several reasons can be proposed to explain this result. First, metformin works by inhibiting the ATP synthesis to increase the AMP or ADP levels in turn indirectly induce the activation of the AMP-activated protein kinase (AMPK) in hepatocytes. AMPK itself has been shown to increase endoplasmic reticulum (ER) stress resistance by the addition of a phosphate group (PO₄)²⁻, reducing inflammation, and finally resulting in conformational and functional changes in the ACE2 receptor through the addition of a phosphate group (PO₄)²⁻. These changes can lead to decreased binding between ACE2 receptor and SARS-CoV-2 Receptor Binding Domain (RBD) due to steric hindrance by the addition of a large sized PO₄ molecule, thus reducing SARS-CoV-2 infectivity (Ursini et al., 2020; Singh et al., 2020). Second, metformin inhibits the mammalian target of rapamycin (mTOR) signaling via liver kinase B1 (LKB1). It also indirectly attenuates AKT activation through phosphorylation of insulin receptor substrate 1 (IRS-1) that resulted in inhibition of the mTOR signaling cascade. The PISK/AKT/mTOR pathway plays a major role in MERS-CoV infection, which may also be implicated in the pathogenesis of SARS-CoV-2 infection, given many similarities between these two viruses. Therefore, inhibition of mTOR by metformin may result in a reduction of SARS-CoV-2 infectivity and mortality from COVID-19 infection (Sharma et al., 2020). Finally, through activation of AMPK, metformin can inhibit the inflammatory response that could potentially contribute to mortality through mechanism such as cytokine storm and vascular damage (Singh et al., 2020; Al-Benna, 2020). Therefore, metformin use will decrease the inflammatory response, reducing the incidence of cytokine storm or vascular damage and finally lead to reduction in mortality rate. Patients with diabetes should hence be advised to continue taking metformin during the COVID-19 pandemic given its potential benefit in reducing the mortality rate of COVID-19. Physicians should also consider adding metformin into the regimen of their diabetes patients’ treatment if the patients have not been given it yet. Finally, the metformin drugs shall be regarded as an important factor in the management plan for COVID-19 patients.

This study has several limitations. First, the presence of confounding factors such as age, other comorbid conditions of patients, and other medications which are taken by patients that can affect the relationship between metformin and the mortality of COVID-19 shall still be considered. Second, no study states the information regarding dosage and duration of metformin treatment in their studied samples, however, we believed that metformin will still give positive impact and benefit from its pharmacodynamics nature regardless of the dosage and duration of treatment. We hope that this study can still give early insight into the further treatment protocol for COVID-19 infections, especially in those with diabetes.

**Table 1** Characteristics of included studies.

| Study | Sample size | Design       | Taking metformin | Not taking metformin |
|-------|-------------|--------------|------------------|---------------------|
|       |             |              | n (%) | Age (years) | n (%) | Age (years) |
| Bramante et al., 2020 | 6256         | Retrospective cohort | 2333 (37.3%) | 73 ± 10.3 | 3923 (62.7%) | 75.6 ± 12.5 |
| Chen et al., 2020 | 120          | Retrospective cohort | 43 (35.8%) | 62.3 ± 9.6 | 77 (64.2%) | 65.8 ± 11.4 |
| Crouse et al., 2020 | 220          | Retrospective cohort | 76 (34.5%) | N/A | 144 (65.5%) | N/A |
| Luo et al., 2020 | 283          | Retrospective cohort | 104 (36.7%) | 62.3 ± 9.2 | 179 (63.3%) | 64.5 ± 10 |
| Wang et al., 2020 | 58           | Retrospective cohort | 9 (15.5%) | N/A | 49 (84.5%) | N/A |

Fig. 1. Forest plot that demonstrates the association of metformin with the mortality rate from COVID-19 infection.

**Funding**

None.

**CRediT authorship contribution statement**

Timotius Ivan Hariyanto: Conceptualization, Data curation, Methodology, Investigation, Validation, Visualization, Writing - original draft, Writing - review & editing. Andree Kurniawan: Conceptualization, Validation, Resources, Writing - original draft, Writing - review & editing, Supervision.

**Declaration of competing interest**

None.

**Acknowledgment**

None.
References

Al-Benna, S., 2020. Association of high level gene expression of ACE2 in adipose tissue with mortality of COVID-19 infection in obese patients. Obes Med 19, 100283. https://doi.org/10.1016/j.obmed.2020.100283.

Bramante, C., Ingraham, N., Murray, T., Marmor, S., Hoversten, S., Gronski, J., et al., 2020. Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19. medRxiv. https://doi.org/10.1101/2020.06.19.20135095, 2020.06.19.20135095.

Chen, Y., Yang, D., Cheng, B., Chen, J., Peng, A., Yang, C., et al., 2020. Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication. Diabetes Care 43 (7), 1399–1407. https://doi.org/10.2337/dc20-0660.

Crouse, A.B., Grimes, T., Li, P., Might, M., Ovalle, F., Shalev, A., 2020. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes. medRxiv. https://doi.org/10.1101/2020.07.29.20164020, 2020.07.29.20164020.

Hariyanto, T.I., Kurniawan, A., 2020a. Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr 14 (5), 1429–1430. https://doi.org/10.1016/j.dsx.2020.07.044.

Hariyanto, T.I., Kurniawan, A., 2020b. Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection. Diabetes Metab Syndr 14 (5), 1463–1465. https://doi.org/10.1016/j.dsx.2020.07.054.

Huang, I., Lim, M.A., Pranata, R., 2020. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia - a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr 14 (4), 395–403. https://doi.org/10.1016/j.dsx.2020.04.018.

Luo, P., Qiu, L., Liu, Y., Liu, X.L., Zheng, J.L., Xue, H.Y., et al., 2020. Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis. Am. J. Trop. Med. Hyg. 103 (1), 69–72. https://doi.org/10.4269/ajtmh.20-0375.

Sharma, S., Ray, A., Sadasivam, B., 2020. Metformin in COVID-19: a possible role beyond diabetes. Diabetes Res. Clin. Pract. 164, 108183. https://doi.org/10.1016/j.diabet.2020.108183.

Singh, A.K., Gupta, R., Ghosh, A., Misra, A., 2020. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr 14 (4), 303–310. https://doi.org/10.1016/j.dsx.2020.04.004.

Urni, F., CIAffi, J., Landini, M.P., Meliconi, R., 2020. COVID-19 and diabetes: is metformin a friend or foe? Diabetes Res. Clin. Pract. 164, 108167. https://doi.org/10.1016/j.diabet.2020.108167.

Wang, B., Van Oekelen, O., Mouhieddine, T.H., Del Valle, D.M., Richter, J., Cho, H.J., et al., 2020. A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. J. Hematol. Oncol. 13 (1), 94. https://doi.org/10.1186/s13045-020-06934-x.